Comparative Clinical Study on Kanashatahwadi Kashaya Ganavati and Capsule Pconidd in Artavkashaya

Abstract

Artavakshaya is characterized by irregularity of cycles, scanty menstruation i.e.; oligomenorrhoea and hypomenorrhoea and pelvic pain due aggravation of vatadosha. Anartava is produced when vatamarga is obstructed by kapha. Due to this vatamargaavrodha, there will be formation of granthi. Polycystic Ovary Disease (PCOD) is one of the most common endocrine disorders among women with reproductive age. PCOD causes artavakshaya. WHO estimates that it affects 116 million women worldwide as 2010 (3.4%women). USG finding of PCO are found in 8.25% of normal women. The present study included comparison between trial groups capsule kanashatahwadi kashaya and capsule Pconidd for artavakshaya lakshana in PCOD. Trial aimed to compare the effect of capsule kanashatahwadi kashaya and capsule Pconidd and its combined effect on artavakshaya lakshana (PCOD). Objective was to evaluate effect of trial drugs on reduction of cyst, decrease of ovarian volume and regularization of menstrual cycle. Study was a randomized open labelled, three arm, comparative clinical trial among 37 subjects fulfilling criteria of diagnosis and inclusion allocated as Gp K(n=10) (Kanashatahwadi kashaya granules) and Gp P(n=10) as capsule Pconidd and combined Gp C(n=10) for a duration of 3 months with 7 drop outs. In Gp K 50% moderately improved, 30% patients markedly improved and 20% patients reported mild improvement. None of patient reported unchanged and complete cured. Total 10 patients completed the treatment in gp P out of which maximum i.e. 60% markedly improved, 30% patients moderate improved, 10% unchanged. Total 10 patients completed the treatment in gp C out of which maximum i.e. 50% unchanged, 30% patients moderate improved, 20% markedly improved. Trial concluded as Gp K was statistically significant in normalizing duration(45.5%)and interval of menstrual cycle(63.7%), improving the quantity of menstruation(81.8%), relieving dysmenorrhoea(59.1%) and in reducing ovarian volume(57.3%). Gp P was significant in regularizing menstrual cycle(44.8%), improving the quantity of menstruation(55.0%), relieving dymenorrhoea(59.9%), reducing ovarian volume(53.8%) and number of cysts (61.7%). Gp C had significant result in regularizing menstrual cycle(61.2%), reducing ovarian volume (50.1%) and the number of cyst(55.4%).